Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-127008
Filing Date
2024-11-14
Accepted
2024-11-14 16:00:32
Documents
83
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q omga-20240930.htm   iXBRL 10-Q 2580416
2 EX-31.1 omga-ex31_1.htm EX-31.1 16375
3 EX-31.2 omga-ex31_2.htm EX-31.2 16432
4 EX-32.1 omga-ex32_1.htm EX-32.1 9292
5 EX-32.2 omga-ex32_2.htm EX-32.2 9384
  Complete submission text file 0000950170-24-127008.txt   9897577

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT omga-20240930.xsd EX-101.SCH 1543862
86 EXTRACTED XBRL INSTANCE DOCUMENT omga-20240930_htm.xml XML 1420577
Mailing Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141
Business Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40657 | Film No.: 241461421
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)